Evidence of platelet activation due to tirofiban-dependent platelet antibodies: double trouble
S Dunkley, R Lindeman, S Evans, R Casten… - Journal of Thrombosis …, 2003 - jthjournal.org
Dear Sir, Thrombocyotopenia associated with the glycoprotein (GP) IIb/IIIa inhibitors is a
recognized entity. Severe thrombocytopenia (< 50Â109 LÀ1) was reported in 0.9% of
patients receiving abciximab in the EPIC trial and is even more common with the oral IIb/IIIa
inhibitors [1, 2]. The rate of severe thrombocytopenia associated with tirofiban is significantly
less common, reported as 0.1% in the TARGET trial, with profound thrombocytopenia (<
20Â109 LÀ1) not seen in the 4800 patients studied compared with an incidence of 0.9% and …
recognized entity. Severe thrombocytopenia (< 50Â109 LÀ1) was reported in 0.9% of
patients receiving abciximab in the EPIC trial and is even more common with the oral IIb/IIIa
inhibitors [1, 2]. The rate of severe thrombocytopenia associated with tirofiban is significantly
less common, reported as 0.1% in the TARGET trial, with profound thrombocytopenia (<
20Â109 LÀ1) not seen in the 4800 patients studied compared with an incidence of 0.9% and …